
"Chemours Audit Unveils Improper Deal Shifting by Suspended Executives"
Chemours placed its CEO and financial executives on leave following an audit alleging ethics violations to secure larger bonuses. The audit revealed efforts to manipulate financial reporting by delaying payments to vendors and accelerating receivables to meet free cash flow targets, a key metric for executive bonuses. The company is re-evaluating its ethics hotline practices and has not released its year-end financial reports. The CEO received over $7.6 million in pay in 2022, with most coming from stock and non-equity incentives. The company's stocks increased by more than 10% in the first minutes of trading on Thursday.







